ReviewJournal of gastrointestinal oncology2026
Risk factors for exclusive lung metastasis in colorectal cancer: a comprehensive narrative review.
Review in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) ranks among the leading causes of cancer-related mortality worldwide, with metastatic spread representing the primary determinant of patient prognosis. Exclusive lung metastasis (ELM) constitutes a distinct metastatic pattern characterized by pulmonary involvement without concurrent extrapulmonary disease, necessitating surveillance and therapeutic approaches that differ from those employed for liver-predominant or multi-organ metastatic disease. This narrative review synthesizes contemporary evidence regarding risk factors associated with ELM development in CRC patients, with the aim of facilitating early detection and enabling risk-stratified surveillance protocols. A comprehensive literature search was conducted across PubMed/MEDLINE, Web of Science, and Google Scholar from database inception through April 24, 2024. English-language human studies investigating clinicopathological, molecular, biomarker, and imaging predictors of CRC lung metastasis were eligible for inclusion, with particular emphasis on ELM. Current evidence demonstrates that ELM risk is multifactorial in nature. Demographic and socioeconomic determinants include advanced age, smoking history, African ancestry, and unmarried or uninsured status. Primary tumor characteristics encompass rectal location, advanced T/N stage, and poor histologic differentiation. At the molecular level, consensus molecular subtype 4 (CMS4) and specific gene alterations confer increased susceptibility. Circulating biomarkers-namely elevated carcinoembryonic antigen (CEA), elevated neutrophil-to-lymphocyte ratio (NLR), and elevated platelet-to-lymphocyte ratio (PLR)-further stratify risk. Select computed tomography (CT) imaging features, including pleural tags, spiculated margins, and radiomic signatures, provide additional predictive value. Integration of these diverse parameters may enhance identification of patients at elevated risk for isolated pulmonary metastatic spread. Comprehensive assessment of clinical, pathological, and molecular characteristics enables informed risk stratification and tailored surveillance strategies. Future investigations should prioritize development and prospective validation of integrated predictive models to guide personalized follow-up protocols and optimize clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.